Dickson et al., 2003 - Google Patents
Photodynamic therapy usingDickson et al., 2003
- Document ID
- 743081378640200723
- Author
- Dickson E
- Kennedy J
- Pottier R
- Publication year
- Publication venue
- Photodynamic Therapy
External Links
Snippet
The use of a harmless drug and ordinary visible light to treat disease may sound like wishful thinking, but the last two decades have shown remarkable progress in the development of such a therapy. However, the concept of a light-activated drug is far from new. Egyptian …
- 238000002428 photodynamic therapy 0 title abstract description 27
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation; Therapies using these preparations
- A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
- A61K41/0071—PDT with porphyrins having exactly 20 ring atoms, i.e. based on the non-expanded tetrapyrrolic ring system, e.g. bacteriochlorin, chlorin-e6, or phthalocyanines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/409—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having four such rings, e.g. phorphine derivatives, bilirubin, biliverdine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation; Therapies using these preparations
- A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
- A61K41/0076—PDT with expanded (metallo)porphyrins, i.e. having more than 20 ring atoms, e.g. texaphyrins, sapphyrins, hexaphyrins, pentaphyrins, porphocyanines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N5/0613—Apparatus adapted for a specific treatment
- A61N5/062—Photodynamic therapy, i.e. excitation of an agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation; Therapies using these preparations
- A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
- A61K41/0061—5-aminolevulinic acid-based PDT: 5-ALA-PDT involving porphyrins or precursors of protoporphyrins generated in vivo from 5-ALA
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K8/00—Cosmetic or similar toilet preparations
- A61K8/18—Cosmetic or similar toilet preparations characterised by the composition
- A61K8/30—Cosmetic or similar toilet preparations characterised by the composition containing organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Aebisher et al. | The use of photodynamic therapy in medical practice | |
| De Rosa et al. | Photodynamic therapy of skin cancers: sensitizers, clinical studies and future directives | |
| Szeimies et al. | Topical photodynamic therapy in dermatology | |
| Calzavara‐Pinton et al. | Photodynamic therapy: update 2006 Part 1: Photochemistry and photobiology | |
| Szeimies et al. | Photodynamic therapy for non-melanoma skin cancer | |
| Juzeniene et al. | Milestones in the development of photodynamic therapy and fluorescence diagnosis | |
| Krammer et al. | ALA and its clinical impact, from bench to bedside | |
| Sakamoto et al. | Photodynamic therapy for acne vulgaris: a critical review from basics to clinical practice: part II. Understanding parameters for acne treatment with photodynamic therapy | |
| AU731042B2 (en) | Photochemotherapeutic compositions | |
| JP5134370B2 (en) | Method for treating acne using a derivative of 5-aminolevulinic acid | |
| EP2120921B1 (en) | Use of aminolevulinic acid and derivatives thereof | |
| Cincotta et al. | Benzophenothiazine and benzoporphyrin derivative combination phototherapy effectively eradicates large murine sarcomas | |
| Fien et al. | Photodynamic therapy for non-melanoma skin cancer | |
| Stritt et al. | Photodynamic therapy in the treatment of actinic keratosis | |
| Silva et al. | Photodynamic therapies: principles and present medical applications | |
| ZA200610239B (en) | Photodynamic therapy for the treatment of hyperactive sebaceous gland disorders using topically applied hydrophobic green porphyrins | |
| Dickson et al. | Photodynamic therapy using | |
| Kassab et al. | Skin-photosensitizing properties of Zn (II)-2 (3), 9 (10), 16 (17), 23 (24)-tetrakis-(4-oxy-N-methylpiperidinyl) phthalocyanine topically administered to mice | |
| WO2009093144A2 (en) | Photodynamic therapy of sebaceous gland disorders | |
| Dragieva et al. | Photodynamic therapy–a new treatment option for epithelial malignancies of the skin | |
| US12544443B2 (en) | Photodynamic therapy comprising two light exposures at different wavelengths | |
| US20240173414A1 (en) | Photodynamic therapy comprising two light exposures at different wavelengths | |
| Maiya | Photodynamic Therapy (PDT) 1. Basic principles | |
| Conway et al. | Photodynamic therapy | |
| Lai et al. | History of photodynamic therapy |